Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-6231 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-6231 Dose Level 1 | EXPERIMENTAL | In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1. In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 1 of mRNA-6231 once every 2 weeks. |
| mRNA-6231 Dose Level 2 | EXPERIMENTAL | In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1. In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 2 of mRNA-6231 once every 2 weeks. |
| mRNA-6231 Dose Level 3 | EXPERIMENTAL | In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1. In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 3 of mRNA-6231 once every 2 weeks. |
| Name | Type | Description |
|---|---|---|
| mRNA-6231 | DRUG | Sterile frozen liquid dispersion for injection |
Key Inclusion Criteria: * Understand and agree to comply with the study procedures and provide written informed consent Key Exclusion Criteria: * Has received any investigational product (for example, study drug, biologic, device) within 30 days or 5 elimination half-lives, whichever is longer * ...
mRNA-6231 is an investigational RNA therapy developed by Moderna, Inc. It is designed to act on IL-2, a cytokine target. It has been studied in a Phase 1 clinical trial in healthy adult volunteers, and the specific medical conditions it may treat have not been disclosed.
mRNA-6231 targets IL-2, which is a cytokine. By encoding for IL-2, the therapy is designed to interact with IL-2 biology. IL-2 is a signaling protein involved in immune cell regulation, and the drug is being developed as an RNA-based approach to this cytokine target.
Moderna, Inc. is developing mRNA-6231. The company trades on the Nasdaq under the ticker symbol MRNA. Moderna is the sponsor of the clinical program for this RNA therapy candidate.
mRNA-6231 is in Phase 1 development. It is an investigational drug and is not approved by the FDA. The Phase 1 study evaluating the candidate has been completed, and no active trials are currently listed for this program.
mRNA-6231 has been evaluated in one clinical trial, NCT04916431, titled a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-6231 in healthy adults. That Phase 1 trial enrolled 18 healthy volunteers in Australia and is completed.